PeptideWise

Editorial Policy

Effective date: April 2026 — Version 1.0

PeptideWise publishes educational content about peptides for informed readers and clinicians. Peptides sit in a rapidly evolving regulatory and scientific landscape, and the quality of what's written about them online varies widely. This policy documents how we decide what to publish, how we cite evidence, and how we handle corrections.

Evidence Standards

Every peptide profile and article on PeptideWise is built from one or more of the following sources:

  • Peer-reviewed studies published in pharmacology, endocrinology, metabolic health, or other recognized medical journals.
  • Systematic reviews and meta-analyses — preferred over single studies when available.
  • FDA labeling, prescribing information, and regulatory filings for approved peptide-based drugs (e.g., semaglutide, tirzepatide).
  • Published clinical guidelines from recognized professional bodies.

Where evidence is limited to animal models, small pilot studies, case reports, or anecdote, we say so. We name the study type, the population, the sample size, and the duration. We do not treat preclinical findings as proof of human effect.

Claim Language

We hold our copy to a deliberate language standard so we do not overstate what the research supports:

  • We use may, might, and suggests— not “will,” “does,” or “proves.”
  • We use correlation and association— not “cause” — unless a specific randomized controlled trial established causation.
  • We do not use “clinically proven,” “doctor recommended,” “medically approved,” or “FDA approved” unless it is literally true for the compound or claim being discussed and we can link the source.
  • We do not claim any peptide will diagnose, treat, cure, or prevent any disease.

Peptides and Regulatory Grey Areas

Many peptides discussed on PeptideWise have varying regulatory statuses — some are FDA-approved drugs, some are dispensed through compounding pharmacies, and some are sold only as research chemicals not approved for human use. Because of this, we apply strict editorial guardrails:

  • No dosage recommendations. We describe dosages used in published studies and cite them. We do not tell a reader what to take.
  • No vendor links. We do not link to research chemical suppliers, grey-market vendors, or compounding pharmacy storefronts. We do not receive affiliate revenue from peptide sales.
  • Regulatory status is disclosed. Every peptide profile notes whether the compound is FDA-approved, available through compounding, or sold only for research use — and that regulatory status can change.
  • Clinician first. We repeatedly direct readers to licensed healthcare providers and pharmacists for anything dose-specific or patient-specific.

Authors and Reviewers

Content is written by the PeptideWise editorial team. Where relevant, individual peptide profiles and articles name a reviewer with their credentials (MD, PharmD, PhD, RN) and the date of the most recent review. We do not fabricate credentials or imply oversight that did not happen.

Review and Update Cadence

Peptide research moves quickly. We prioritize re-reviewing:

  • High-traffic peptide profiles (semaglutide, tirzepatide, BPC-157, TB-500, retatrutide).
  • Profiles for compounds whose regulatory status or FDA labeling changes (including new black-box warnings or new indications).
  • Articles whose underlying studies have been retracted, superseded, or substantially updated.

When an update changes the substance of a profile, we bump the “last reviewed” date and note what changed.

Editorial Independence

PeptideWise editorial content is created independently. We do not accept payment to feature, rank, or review specific peptides, compounds, clinics, or compounding pharmacies. We cross-link to PeptideTracker (our own mobile app) where contextually relevant — those links are always labeled as internal to our portfolio and are not sponsored placements.

If we ever introduce affiliate relationships or sponsored content, we will disclose those relationships inline with the relevant content, in accordance with FTC guidelines.

Corrections

When we identify an error, or when a reader or researcher brings one to our attention:

  • Minor corrections (typos, broken links, formatting): fixed promptly, no notice.
  • Factual corrections(misquoted studies, incorrect mechanism descriptions, wrong regulatory status): fixed and the “last reviewed” date is bumped.
  • Significant corrections (retracted source, new safety data, superseded guidance): a short correction note is added to the affected page explaining what changed and why.

Report an Issue

If you believe a peptide profile, article, or calculator on this site contains an error, is outdated, or could mislead a reader, please let us know. Include the page URL, the specific issue, and any supporting references. Contact us at contact@getpeptidewise.com. We welcome feedback from readers, researchers, clinicians, and pharmacists.

Related Policies